Daan Gene

Executive Summary

Daan Gene is a leading Chinese in-vitro diagnostics company specializing in PCR-based testing for infectious diseases and genetic analysis. The company gained prominence during the COVID-19 pandemic as a key supplier of diagnostic kits and instruments, and has since leveraged its expertise to become a major player in infectious disease surveillance and molecular diagnostics. With over 20 years of history and a strong domestic presence, Daan Gene is well-positioned to benefit from China's ongoing investments in public health infrastructure and the growing demand for precision medicine. However, post-pandemic normalization has led to revenue declines, and the company faces intense competition from other domestic IVD players like BGI Genomics and Sansure Biotech. To sustain growth, Daan Gene is expanding into new areas such as sexually transmitted infection (STI) testing, hepatitis testing, and cancer screening, while also pursuing international expansion in emerging markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation STI and hepatitis multiplex PCR panels in China80% success
• Q4 2026Regulatory approval for cancer screening liquid biopsy tests (e.g., colorectal cancer)60% success
• Q2 2026Expansion into Southeast Asian and African markets via new distribution partnerships70% success